Calcium antagonists in African-American patients.
When initiating monotherapy for the treatment of essential hypertension, multiple determinants factor into the decision. The goal of treatment is to lower blood pressure and lessen the likelihood of progression to target organ failure. Physicians frequently prioritize these determinants and make decisions to initiate monotherapy based on the race of an individual. All too often, however, the black/white issue is overstated and given too much consideration. The overall goal of this review is to suggest the appropriate "role" for racial profiling in the initial selection of an antihypertensive agent.
Jamerson
K
K
University of Michigan, Ann Arbor, USA.
D001741:Black or African American; D044383:Black People; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000208:ethnology* / Q000503:physiopathology; D008019:Life Style; D010953:Plasma Volume; D018434:Sickness Impact Profile; D014481:United States / Q000453:epidemiology
D002121:Calcium Channel Blockers